Literature DB >> 12237032

[Profile of patients under treatment with heparin of low molecular weight].

M Garrote García, M J Iglesias Piñeiro, A López Gil, R Martín Alvarez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12237032      PMCID： PMC7668977          DOI： 10.1016/s0212-6567(02)79018-5

Source DB:  PubMed          Journal:  Aten Primaria        ISSN： 0212-6567            Impact factor:   1.137


× No keyword cloud information.
  7 in total

Review 1.  The venous thrombotic risk in nonsurgical patients.

Authors:  J Bouthier
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 2.  Prevention of venous thromboembolism.

Authors:  G P Clagett; F A Anderson; W Geerts; J A Heit; M Knudson; J R Lieberman; G J Merli; H B Wheeler
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

3.  [The home treatment of deep venous thromboses with low-molecular-weight heparin].

Authors:  E Grau Segura; E Real Vila; E Pastor Guzmán; J A Torró Richart; M Garay Burdeos
Journal:  Rev Clin Esp       Date:  1997-06       Impact factor: 1.556

Review 4.  Deep-vein thrombosis.

Authors:  E E Weinmann; E W Salzman
Journal:  N Engl J Med       Date:  1994-12-15       Impact factor: 91.245

5.  Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection.

Authors:  P S Wells; M J Kovacs; J Bormanis; M A Forgie; D Goudie; B Morrow; J Kovacs
Journal:  Arch Intern Med       Date:  1998-09-14

Review 6.  International consensus recommendations. Summary statement and additional suggested guidelines. European Consensus Conference, November 1991. American College of Chest Physicians consensus statement of 1995. International Consensus Statement, 1997.

Authors:  R L Bick; S K Haas
Journal:  Med Clin North Am       Date:  1998-05       Impact factor: 5.456

7.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.